Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by GameChangerBeton Jun 07, 2021 7:13pm
221 Views
Post# 33345221

RE:RE:RE:RE:Hoping they provide an update soon

RE:RE:RE:RE:Hoping they provide an update soonDo you really need to be told why it is wrong? 

The statement was: "People stay because they are at loss. Keep that in mind"

This is one of the worst, if not the absolute worst reason to stay in a stock.
You should stay in a stock because the fundamentals and facts warrant such a position.


Aside from a money management or portfolio adjustment aspect, being at a loss should never be a reason to stay in. That's why retail folks ride stocks down to zero, because of that mentality.

In regards to the comment about criticizing the company, let me make it very clear for you and anyone else interested, I couln't care in the least about the company or any other company outside of how it may impact my investment. I have only one objective, which is to make a return on my investment. However in the case of Antibe, they are embarked on a path of producing safer medicines, which I would absolutely cheer for just as a human.

And as far as I'm concerned about the stock, this can stay dead money for another 3 years for all I care. I am interested in the actual long term outcome.
In terms of all those catalysts being talked about, I have a general sense of possible time frames and what I think the plan is, but they'll come when they come.

The end result will outweigh any perceived missteps that may occur along the way. 
That's the reason I stay in.

Be smart, don't be a fool.





123ABC wrote: Don't worry GamePumper should be here soon to tell you why you're wrong and that you should sell for criticizing the company.


<< Previous
Bullboard Posts
Next >>